155 results on '"Zhou, Ai-Ping"'
Search Results
2. Prognosis and Clinicopathological Characters of Adult TFEB-Altered Renal Cell Carcinoma: A Single Center Experience of 18 Cases
3. High Expression of Cancer-derived Immunoglobulin G is Associated with Poor Survival in Metastatic Clear Cell Renal Cell Carcinoma
4. Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair/microsatellite instability high solid tumors
5. Study on the two-dimensional kinetic Ising model with the dynamic Monte Carlo renormalization group method
6. Prognosis and clinicopathological characters of adult TFEB-altered renal cell carcinoma: a single center experience of eighteen cases
7. Comparison of 627 patients with right- and left-sided colon cancer in China: Differences in clinicopathology, recurrence, and survival
8. Serum IgG: A potential biomarker for predicting the efficacy of systemic therapy in metastatic renal cell carcinoma.
9. High expression of sialylated cancer-derived IgG and survival in metastatic clear cell renal cell carcinoma.
10. Neutrophil extracellular traps in relation to efficacy of systemic therapy for metastatic renal cell carcinoma.
11. Theoretical insights on the luminescent mechanism of a highly efficient green-activated delayed fluorescence emitter using the QM/MM method
12. Dynamic alteration and prognostic significance of tumor‐associated CD68 + and CD68 + PD‐L1 − macrophages in muscle‐invasive bladder cancer treated with neoadjuvant chemotherapy
13. MRG002-006: A multicenter phase II clinical trial of MRG002-ADC for unresectable locally advanced or metastatic urothelial cancer.
14. A phase Ib study of anlotinib plus TQB2450 as a second-line investigational therapy in advanced hepatocellular carcinoma (aHCC).
15. Biweekly mXELIRI versus FOLFIRI in combination with bevacizumab as the first-line treatment for metastatic colorectal cancer (EXIST): A multicenter, randomized, open-label, phase 2 study.
16. Perioperative chemotherapy with docetaxel plus oxaliplatin and S-1 (DOS) versus oxaliplatin plus S-1 (SOX) for locally advanced gastric or gastro-esophageal junction adenocarcinoma (MATCH): An open-label, randomized, phase 2 study.
17. Assessment of a HER-2 scoring system and its correlation of HER2-targeting antibody-drug conjugate therapy in urothelial carcinoma.
18. Preliminary results of raltitrexed in Chinese patients with metastatic colorectal cancer: A prospective, multicenter, real-world study.
19. Oxaliplatin and capecitabine (XELOX) plus toripalimab as perioperative treatment for locally advanced gastric or gastro-esophageal junction adenocarcinoma (Neo-Capture): A single-arm, phase 2 study.
20. Multicenter, Randomized, Phase III Trial of Short-Term Radiotherapy Plus Chemotherapy Versus Long-Term Chemoradiotherapy in Locally Advanced Rectal Cancer (STELLAR)
21. Final clinical outcome and biomarker analysis of sintilimab plus a bevacizumab biosimilar (IBI305) for advanced hepatocellular carcinoma: A phase Ib clinical trial.
22. Nab-paclitaxel plus sintilimab as second-line therapy for advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJA): Preliminary results from an open-label, single-arm, phase 2 study.
23. An open-label, multicenter, randomized controlled study of mXELIRI versus FOLFIRI in combination with bevacizumab as the first-line treatment in metastatic colorectal cancer: A single-center report.
24. Mechanism of fluidized chlorination reaction of Kenya natural rutile ore
25. Dynamic alteration and prognostic significance of tumor‐associated CD68+ and CD68+PD‐L1− macrophages in muscle‐invasive bladder cancer treated with neoadjuvant chemotherapy.
26. Structure and stability of magnetized accretion disks with anomalous viscosity
27. Study on the instability of accretion disks with anomalous viscosity
28. The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021
29. Additional file 1 of Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair/microsatellite instability high solid tumors
30. Vorolanib, everolimus, and the combination in patients with pretreated metastatic renal cell carcinoma (CONCEPT study): A randomized, phase 3, double-blind, multicenter trial.
31. Efficacy, treatment modalities, and safety of regorafenib in Chinese metastatic colorectal cancer patients: A multiple centers real-world study.
32. An open-label, single-arm, multicenter, phase II study of RC48-ADC to evaluate the efficacy and safety of subjects with HER2 overexpressing locally advanced or metastatic urothelial cancer (RC48-C009).
33. Prophylactic Antiviral Therapy in Low-Risk Patients infected with the Hepatitis B Virus with Solid Tumors
34. Famitinib in metastatic renal cell carcinoma: a single center study
35. A phase II trial of oxaliplatin plus S-1 as a first-line chemotherapy for patients with advanced gastric cancer
36. High dose chemoradiotherapy with autologous hematopoietic stem cell transplantation in the treatment of advanced Hodgkin’s lymphoma: A report of 11 cases
37. Anlotinib for Patients With Metastatic Renal Cell Carcinoma Previously Treated With One Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor: A Phase 2 Trial
38. A phase II study of RC48-ADC in HER2-positive patients with locally advanced or metastatic urothelial carcinoma.
39. Nab-paclitaxel plus S-1 as first line treatment for advanced or metastatic biliary tract adenocarcinoma: A phase 2 study.
40. Different expression and prognostic implications of PD-L1 in tumor cells and immune cells with the SP263 monoclonal antibody in Chinese urothelial carcinoma patients.
41. Anlotinib Versus Sunitinib as First-Line Treatment for Metastatic Renal Cell Carcinoma: A Randomized Phase II Clinical Trial
42. Suppression of resonant auger effect with chirped x-ray free-electron laser pulse
43. Study on the phase transition of the fractal scale-free networks
44. Outcome of chemotherapy with or without targeted therapy in metastatic colorectal cancer with deficient mismatch repair phenotype: A cohort study in a single center.
45. Vorolanib (CM082) in Chinese patients with advanced solid tumor: A phase 1, open-label, dose escalation study.
46. Effects of neoadjuvant chemotherapy on immune microenvironment and clinical outcomes in locally advanced gastric cancer.
47. Efficacy and safety of pazopanib (PAZ) versus sunitinib (SUN) in patients (pts) with locally advanced or metastatic renal cell carcinoma (RCC): A pooled China subgroup analysis from COMPARZ studies.
48. Vorolanib (CM082), everolimus, and the combination in patients with pretreated metastatic renal cell carcinoma (CONCEPT study): A randomized, phase 2/3, double-blind, multi-center trial.
49. Efficacy and safety of nab-paclitaxel plus s-1 in the first-line treatment of advanced pancreatic cancer.
50. Streptococcus agalactiae Inhibits Candida albicans Hyphal Development and Diminishes Host Vaginal Mucosal TH17 Response
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.